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1. Introduction
Social cognition has been described as the “mental operations underlying social interactions,
which include the human ability and capacity to perceive the intentions and dispositions of
others” (Brothers 1990). Adolphs (2001) identified social cognition as “the ability to construct
representations of the relation between oneself and others and to use those representations
flexibly to guide social behavior.” These definitions suggest that social cognition is a set of
related processes applied to the recognition, understanding, accurate processing, and effective
use of social cues and information in social situations (Penn et al. 1997).
A key aspect of social cognition is emotion perception. Reviews indicate that individuals with
schizophrenia have deficits in emotion perception relative to non-clinical controls (e.g.,
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Edwards et al. 2002; Hellewell et al. 1998; Kohler and Brennan 2004; Mandal et al. 1998) with
these impairments being related to functional outcomes (Couture et al. 2006). Thus, emotion
perception might be an important treatment target, as improvement in emotion perception
might result in subsequent improvement in functional outcomes.
Pharmacological intervention studies on social cognition have been rather limited. Littrell et
al. (2004) and Kee et al. (1998) found that olanzapine and risperidone, respectively, was
associated with improved social perception relative to conventional antipsychotic medication.
However, both studies suffer from signfiicant limitations. First, sample sizes were small,
particularly for Kee et al.(N=18). And second, Littrell et al. (2004) did not utilize random
assignment. In another pilot study, Herbener et al. (2005) found that antipsychotic medications
did not improve emotion perception in 13 individuals with first episode psychosis. Harvey et
al. (2006) found that neither quetiapine nor risperidone resulted in improved emotion
perception among 289 individuals with schizophrenia. Sergi et al (2007) found that neither
risperidone, olanzapine, or haloperidol improved emotion perception among 100 oupatients
with schizophrenia or schizoaffective disorder. Since Harvey et al. (2006) and Sergi et al
(2007) were the only adequately powered studies, it is difficult to draw any confident
conclusions regarding antipsychotic medication effects on emotion perception based on
previous research. Furthermore, only Sergi et al. (2007) has examined the impact of multiple
atypical medications compared to a typical antipsychotic in a large, stable, chronically ill
population with schizophrenia.
The National Institute of Mental Health (NIMH) sponsored Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) trial included a measure of emotion perception in the
design (Stroup et al. 2003): This led to the formulation of two research questions. First, would
there be significant differences among olanzapine, perphenazine, quetiapine, risperidone, and
ziprasidone in improvement in emotion perception as measured by the Face Emotion
Discrimination Test (FEDT)(Kerr and Neale 1993) from baseline to two months? And second,
which baseline variables predict improvement in emotion perception over two months?
2. Methods
2.1 Study Setting and Design
The CATIE study was conducted from January 2001 until December 2004 at 57 U.S. clinical
sites, including 16 university clinics, 10 state mental health agencies, seven VA Medical
Centers, six private nonprofit agencies, four independent practice sites, and 14 mixed system
sites. A complete description of study rationale, design, and methods has been previously
documented (Davis et al. 2003; Keefe et al. 2003; Lieberman et al. 2005; Stroup et al. 2003).
Patients were randomly assigned under double blind conditions to one of five medications:
olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone (Lieberman et al. 2005).
They were followed for up to 18 months or until treatment was discontinued for any reason
(phase 1).
The inferential analyses in this report are limited to the results from phase 1 because of the
expectation that most of the treatment effects should occur within the first 2 months of
treatment. The CATIE Neurocognition Advisory Group reviewed the literature available at the
time the cognition analyses were performed and determined that the majority of cognitive
improvement with antipsychotic treatment takes place in the first 2 months of treatment
(including that for emotion perception, which was part of the neurocognitive battery). This was
largely confirmed by the neurocognitive findings from the CATIE study (Keefe et al. 2007a).
Penn et al. Page 2
Schizophr Res. Author manuscript; available in PMC 2010 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Participants
2.2 Subjects—Eligible patients were 18 to 65 years of age; had received a diagnosis of
schizophrenia, as determined on the basis of the Structured Clinical Interview of the Diagnostic
and Statistical Manual of Mental Disorders, fourth edition; and were able to take oral
antipsychotic medication. 1493 patients with a diagnosis of schizophrenia, confirmed by the
SCID (First et al. 1994), were entered into the study from 57 institutions. Patients were excluded
if they had diagnosis of schizoaffective disorder, mental retardation or other cognitive
disorders; had a history of serious adverse reactions to the proposed treatments; had had only
one schizophrenia episode; had a history of treatment resistance, defined by persistence of
severe symptoms despite adequate trials of one of the proposed treatments or prior treatment
with clozapine (see Lieberman et al., (2005) for how this was defined); were pregnant or were
breast-feeding; or had a serious and unstable medical condition. There were no exclusion
criteria based upon symptoms.
The institutional review board approved this study at each site. Also, written informed consent
was obtained from the patients or their legal guardians at each site.
Interventions
2.3 Treatment—Identical-appearing capsules contained olanzapine (Zyprexa, Eli Lilly) (7.5
mg), quetiapine (Seroquel, AstraZeneca) (200 mg), risperidone (Risperdal, Janssen
Pharmaceutica) (1.5 mg), or perphenazine (Trilafon, Schering-Plough) (8 mg) or (after January
2002) ziprasidone (Geodon, Pfizer) (40 mg). The packaging was done by Quintiles. The dose
of the medications was flexible, ranging from one to four capsules daily, based upon the study
doctor’s judgment. Relative tablet strength was reviewed by senior representatives from each
drug manufacturer. Overlap in the administration of the antipsychotic agents that patients
received before study entry was permitted for the first four weeks after randomization to allow
a gradual transition to study medication. Concomitant medications were permitted throughout
the trial, except for additional antipsychotic agents. Patients had monthly visits with study
doctors.
Because of product labeling, quetiapine or ziprasidone were given twice daily and olanzapine,
perphenazine, and risperidone once daily. To protect blinding, half the patients randomly
assigned to perphenazine, olanzapine, and risperidone were assigned to twice-daily dosing and
half to once-daily dosing. To minimize initial side effects, patients assigned to quetiapine began
treatment by receiving one 100-mg capsule on days 1 and 2, one twice daily on day 3, and one
for the first dose of day 4. All patients assigned to twice daily dosing received five identical-
appearing capsules to begin treatment. Patients with current tardive dyskinesia based on
Schooler-Kane criteria were randomized to treatments other than perphenazine.
2.4 Primary Outcome Measure—The FEDT is comprised of 30 pairs of faces presented
concurrently with no time limit, and requires the participant to determine if the two faces in
each pair are displaying the same or different emotions (Kerr and Neale 1993). It is a widely
used measure of emotion perception with sound psychometric properties (Penn et al. 2006).
We selected an emotion discrimination rather than identification task because the latter task is
partially mediated by verbal functioning, and our battery already had verbal memory, verbal
fluency, and verbal working memory tasks. Thus, we wanted to utilize a social cognition task
that was less influenced by verbal processes. A commonly used method for administering the
FEDT is via videotape. However, since this method may have been too difficult to implement
at a 57-site study, laminated printouts of the faces were used instead. Performance on the FEDT
was indexed as the total number of correct responses.
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2.5 Statistical Analysis—For consistency with other CATIE publications, the statistical
analyses conducted in this study were similar to those conducted on neurocognition from the
CATIE trial (Keefe et al. 2007a). Our goal was to compare the groups on the change in FEDT
scores from baseline to month 2. our primary analyses compared treatment groups on FEDT
change scores from baseline to month 2 using analysis of covariance (ANCOVA), controlling
for baseline FEDT performance; whether the patient had required crisis stabilization in the 3
months prior to study entry defined as exacerbation status, and TD status except where not
applicable, as described below. Crisis stabilization was designated a priori as a potentially
important covariate in the CATIE protocol and it was included in the current analyses so as to
examine whether clinical state at entry could influence changes in social cognition (as well as
to be consistent with the original CATIE protocol). This analysis allowed us to examine
whether the change for each treatment significantly differed from zero (essentially testing a
time effect within each treatment).
The FEDT scores had a ceiling effect and negative skew (Keefe et al. 2006) (See Table one).
However, the change-score (FEDT 2-month scores minus FEDT baseline scores), the
dependent variable, had an approximately normal distribution, with the scores being
symmetrical.
Since patients with TD were not randomized to perphenazine, all analyses containing
perphenazine were limited to the cohort of patients without TD. Also, since ziprasidone was
added to the trial after 40% of the patients were randomized, all analyses containing ziprasidone
involved a subset of the total sample. Treatment group comparisons were therefore conducted
on four analytic data sets with overlapping membership based on the TD and ziprasidone cohort
stratification. Each data set only included subjects who had an equal chance of randomization
to the treatments under comparison. Perphenazine subjects, in particular, were only compared
to equivalent subjects who did not have TD at baseline, and ziprasidone subjects were only
compared to subjects who were enrolled after ziprasidone was added.
Using this ANCOVA model, we evaluated the overall statistical significance between
perphenazine, olanzapine, quetiapine, and risperidone, excluding patients with TD, relative to
p=.05 (i.e., Data Set I). If the overall test was statistically significant, perphenazine was then
compared with each of the atypical antipsychotics using a Hochberg modification of the
Bonferroni correction for multiple treatment comparisons. Specifically, the largest p-value was
compared to 0.05 and the smallest p-value was compared to .05/3=0.017. We then compared
the three atypical drugs (olanzapine, quetiapine, and risperidone), including patients with TD,
relative to p=.05 (i.e., Data Set II). TD was included as an additional covariate and we also
checked for a TD by treatment interaction. Pair-wise comparisons were evaluated only if the
overall treatment p-value was ≤.05. In the third analysis, we compared ziprasidone and
perphenazine, using the subset of patients enrolled after ziprasidone was added and excluding
patients with TD, relative to p=.05 (i.e., Data Set III). Finally, we compared ziprasidone with
olanzapine, quetiapine, and risperidone, using the subset of patients enrolled after ziprasidone
was added and including patients with TD (Dataset IV). Ziprasidone was compared versus the
other four treatments in Data Sets III and IV using a Hochberg adjustment in which the smallest
p value was compared relative to 0.05/4=0.0125.
Potential baseline covariates were identified a priori by reviewing previous research on social
cognition in schizophrenia (Penn et al. 1997). These covariates included gender, years of
education, years since first prescribed an antipsychotic medication, alcohol status,
neurocognitive composite score, reading subset of the WRAT, Quality of Life (QOL)
Interpersonal Relations Scale, and the PANSS positive and negative scales. The neurocognitive
composite score was calculated by creating a z-score of the average of five standardized domain
scores (i.e., processing speed, reasoning, working memory, verbal memory, and vigilance).
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An ANCOVA model was computed including these covariates simultaneously, as well as
investigator site, pooled into 6 groups based on site care setting, and exacerbation status, and
served to determine predictors of emotion perception improvement on the FEDT.
3. Results
3.1 Characteristics and dispositions of patients
There were 1460 randomized patients available for analysis (Lieberman et al. 2005). The
primary cohort for this report consisted of 873 patients who completed the FEDT immediately
prior to randomization and 2 months post-baseline. Twenty five percent of these patients were
antipsychotic free at baseline, while 60% reported being on a second generation antipsychotic,
and 15% were on a first generation antipsychotic.
Table 1 summarizes the demographic and clinical characteristics of patients who completed
the FEDT at baseline and at 2 months (N=873), and those who only completed the baseline
assessment (N=515). Participants tested at baseline and month 2 were older, less symptomatic,
more likely to be taking olanzapine monotherapy or risperidone monotherapy or any type of
antipsychotic treatment at baseline than patients who only completed the FEDT at baseline.
Participants with 2 month FEDT data were compared across treatment groups and no major
differences were found for the important covariates.
3.2. Primary analyses: Face emotion test changes after 2 months of treatment
Table 2 and Figure 1 present mean and standard deviation FETD change from baseline to 2
months across the 4 analysis datasets. A one-way ANCOVA for patients without TD revealed
that there was no overall significant difference among the 4 treatment groups F=. 30 (p=.82),
(Data Set I). In examining individual treatment changes, the perphenazine FEDT ANCOVA
least-square mean change score was .54 (p = .01). Least-square mean change scores observed
for the quetiapine, .36, (p=.09), risperidone, .35 (p = .09) and olanzapine, 0.27 (p=.19) groups
were not significantly different than zero (Data Set I).
We then included patients with TD in the analyses to compare the three atypical antipsychotic
groups (Data Set II). There was no overall difference in FEDT change among the treatment
groups (p=.99). The magnitude of change among the groups was very similar to the analyses
from Data Set I. None of the three groups showed a FEDT least square mean change score
significantly different than zero (olanzapine, 0.35 (p=.053), quetiapine, 0.34 (p=.07), and
risperidone, 0.32 (p=0.09). There was no difference in FEDT change scores between TD and
non TD patients within Data Set 2 (t=.90, p=.37), and no TD by treatment group interaction
(p=.99).
Change in the FEDT from baseline to 2 months was examined in the perphenazine and
ziprasidone groups excluding patients with TD (Data Set III). There was no difference between
the treatment groups .64 (p=.43). The perphenazine group had an FEDT least-square mean
change score of .13 (p=.66) while the group receiving ziprasidone had a least-square mean
change score of −.23 (p=.50).
We then examined change in the FEDT in the ziprasidone group relative to the three other
atypical medication groups in patients with TD (Data Set IV). There was no overall difference
among the treatment groups (p=.77). FEDT least-square mean change scores were not different
than zero for patients receiving olanzapine, 0.44 (p=.13), quetiapine, 0.37 (p=.18), risperidone,
0.47 (p=.11), and ziprasidone, 0.07 (p=.81).
Effect sizes were small for all treatment groups in all four Data Sets and ranged from .04 to .
18. The pattern in findings, specifically the overlap in confidence intervals, shows that changes
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in emotion perception were relatively equivalent across medications (and for all data sets)
(Figure 1).
3.3 Predictors of emotion perception improvement
Baseline FEDT score was mildly correlated with most of the predictors at both baseline and 2
month follow-up (Table 3). Prediction of improvement in FEDT from baseline to two months
was examined using an ANCOVA. Lower baseline FEDT score and higher baseline
neurocognitive composite score (p<.001) were significant predictors of greater improvement
in emotion perception; fewer years on antipsychotic medication was a weak predictor (p=0.06)
(see Table 4).
4. Discussion
This study examined whether second-generation antipsychotic medications would result in
greater improvement in emotion perception compared to a first generation antipsychotic
medication. The results showed that patients in all treatment groups (with the exception of
ziprasidone) showed small, non-significant improvements in emotion perception from baseline
to two months. However, there were no differences between the medications on emotion
perception change. These findings are consistent with the CATIE results for neurocognition
(Keefe et al. 2007a) and psychosocial functioning (Swartz et al. 2007) as well as previous
research showing limited medication effects on social cognition (Harvey et al. 2006; Sergi et
al. 2007). We also found that improvement in emotion perception was significantly associated
with lower baseline emotion perception and better neurocognition.
The effect of newer-generation, “atypical” antipsychotic medications on neurocognition in
patients with schizophrenia has been controversial (the impact of atypicals on social cognition
is a newer area). While many studies and meta-analyses (Harvey and Keefe 2001; Keefe et al.
1999; Woodward et al. 2005) have suggested that second-generation antipsychotic treatment
provides greater neurocognitive benefit to schizophrenia patients than first-generation,
“typical” antipsychotics, many of these studies have had substantial methodological
weaknesses. Analyses of the effects of antipsychotic medications on cognition in the CATIE
trial suggested that there were no differences between the atypical medications and the
representative medication perphenazine (Keefe et al. 2007a). The magnitude of the
performance improvements demonstrated in this trial and others have been interpreted as
consistent with practice effects (Keefe et al. 2007a; Keefe et al. 2007b; Nuechterlein et al.
2008). Although practice effects cannot be ruled out in the present study due to the absence of
a control or placebo groups, repeated assessment on emotion perception tests does not typically
correspond to task improvement (Penn and Combs 2000). This underscores the need to design
studies that will clearly identify whether improvements in emotion perception, even small ones,
are due to practice effects or treatment.
Better neurocognitive functioning at baseline (as well as poorer emotion perception) was
associated with improvement in emotion perception at two months. These findings are
congruent with a growing applied research base which shows that improving neurocognition
(via psychosocial interventions) may result in improved functioning in more molar domains,
such as social cognition, and social and work functioning (McGurk and Mueser 2006; McGurk
and Mueser 2004; McGurk et al. 2005; Silverstein et al. 2005; Silverstein et al. 2006; Wexler
and Bell 2005). Therefore, better neurocognition may provide traction for improvement in
emotion perception (and other more molar functional outcomes) to occur.
In closing, the results suggest that antipsychotic medications have a small, non-statistically
significant impact on emotion perception. Interpretation of these results needs to be tempered,
as the FEDT is only a single measure of emotion perception, and other domains, such as
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emotion identification, were not assessed. And the absence of a placebo control group prevents
confident conclusions that the any improvements (albeit small) were due specifically to the
medications. In addition, administration of the FEDT was modified to meet the needs of a large
multi-site battery (such as the exposure time of the stimuli), which might have changed it is
psychometric properties and contributed to the negative skew of the baseline data (as 59% of
the sample scored 25 or higher on the FEDT at baseline; Table 1). This, in turn, may have
attenuated the effects of treatment due to the easiness of the test (although performance on the
FEDT by participants in this study was comparable to other research using this measure)
(Pinkham and Penn 2006). Thus, it appears that other strategies, such as psychosocial
approaches targeting social cognition (reviewed in Horan et al. 2008), need to be utilized to
improve emotion perception in schizophrenia.
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Figure 1.
Mean FEDT Baseline to Month 2 Change Scores for Data Sets I, II, III, and IV with 95%
confidence intervals
Note: Olz = Olanzapine; P = Perphenazine; Q = Quetiapine; R = Risperidone; Z = Ziprasidone
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Table 1
Demographic and Baseline Characteristics of Patients with FEDT Data
BL Data and Month 2 Data
Available (N=873)
BL Data Available but Month 2
Data Not Available (N=515)
P-value for comparing patients with Month 2
Data vs. without
Variable Mean(SD) or N(%) Mean(SD) or N(%) T or Chi-Square statisticp-value
Age(years) 40.96(10.91) 39.66(11.30) 2.13 0.03
Patient’s Education (years) 12.18(2.20) 12.08(2.25) 0.75 0.45
Duration Since First Prescribed
Antipsychotic Medication (years)
14.49(10.92) 14.17(10.40) 0.53 0.60
PANSS(total score) 74.29(17.48) 77.09(17.27) −2.89 <0.001
Sex
 Male 655(75.03%) 380(73.79%) 0.26 0.61
 Female 218(24.97%) 135(26.21%)
Race
 White 534(61.24%) 302(58.75%) 0.86 0.35
 Other 338(38.76%) 212(41.24%)
Ethnic Origin
 Hispanic 95(10.88%) 158(30.68%) 0.05 0.83
Baseline Antipsychotic Medications
 Olanzapine alone 213(24.40%) 99(19.22%) 4.98 0.03
 Quetiapine alone 54(6.19%) 36(6.99%) 0.35 0.56
 Risperidone alone 183(20.96%) 83(16.12%) 4.90 0.03
 Any combination which includes
olanzapine, quetiapine, or risperidone
72(8.25%) 52(10.10%) 1.36 0.24
 All others 130(14.89%) 87(16.89%) 0.98 0.32
 None 221(25.32%) 158(30.68%) 4.70 0.03
 Baseline FEDT 24.58(3.40) 24.19(3.53) 0.43 0.67
 Median Baseline FEDT 25.00
 Frequency Baseline FEDT (for BL and
Month 2 Data)
<20 N (%) 20–24 N (%) 25–28 N (%) 29–30 N (%)
60 (6.87%) 298 (34.14%) 460 (52.69%) 55(6.30%)
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Table 3
Correlation between Predictors and Baseline and 2 month FEDT Scores
Baseline FEDT 2 month FEDT
Number of Years of Patient’s Education .13** .16**
Years Since First Prescribed an Antipsychotic Medication −.16** −.19**
Baseline Neurocognitive Composite Score .32** .34**
Reading Subtest of the WRAT .25** .26**
Baseline QOL Interpersonal Relations .10** .06
Baseline PANSS Negative Scale −.16** −.14**
Baseline PANSS Positive Scale −.086** −.03
Gender (t-test) t=2.03, p=.03 t=3.80, p < .01
Alcohol Status (ANOVA) F=0.52, p=.59 F=.21, p=.81
*
Note: p<.05,
**
p<.01
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Table 4
Prediction of change in FEDT performance at two months from baseline variables
Variable Regression Coefficient Standard Error t-value p-value
Baseline FEDT score −0.50 0.03 −14.47 <.0001
Gender (1=male, 2=female) 0.44 0.25 1.73 0.08
Number of Years of Patient’s Education 0.06 0.06 1.17 0.24
Years Since First Prescribed an
Antipsychotic Medication
−0.02 0.01 −1.88 0.06
Alcohol Status (0=abstinence, 1=use,
2=abuse)
0.21 0.13 1.64 0.10
Baseline Neurocognitive Composite Score 0.45 0.13 3.36 <.001
Reading Subtest of the WRAT 0.02 0.01 1.49 0.14
Baseline QOL Interpersonal Relations −0.06 0.09 −0.77 0.44
Baseline PANSS Negative Scale 0.01 0.02 0.23 0.82
Baseline PANSS Positive Scale −0.01 0.02 −0.64 0.52
Requiring crisis stabilization in the 3
months prior to study entry (exacerbation
status)
−0.05 0.24 −0.22 0.82
Investigator site, pooled into 6 groups based
on site care setting
-- -- -- 0.27
Note: All of the above variables were entered simultaneously. Model R2 = 0.31
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